RU2013157040A - POLYVALENT ANTIGEN-BINDING FV-MOLECULE - Google Patents
POLYVALENT ANTIGEN-BINDING FV-MOLECULE Download PDFInfo
- Publication number
- RU2013157040A RU2013157040A RU2013157040/10A RU2013157040A RU2013157040A RU 2013157040 A RU2013157040 A RU 2013157040A RU 2013157040/10 A RU2013157040/10 A RU 2013157040/10A RU 2013157040 A RU2013157040 A RU 2013157040A RU 2013157040 A RU2013157040 A RU 2013157040A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- domain
- binding molecule
- polypeptide
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1. Димерная антиген-связывающая молекула, состоящая из первой и второй полипептидной цепи, причем каждая из указанных первой и второй полипептидных цепей содержит:- первый домен VA, являющийся вариабельным доменом легкой цепи, специфичным по отношению к первому антигену A;- второй домен VB, являющийся вариабельным доменом тяжелой цепи, специфичным по отношению ко второму антигену B;- третий домен VB, являющийся вариабельным доменом легкой цепи, специфичным по отношению ко второму антигену B; и- четвертый домен VA, являющийся вариабельным доменом тяжелой цепи, специфичным по отношению к первому антигену A,причем- указанные домены расположены в каждой из указанных первой и второй полипептидных цепей в порядке VA-VB-VB-VA от N-конца к C-концу указанных полипептидных цепей, и- первый домен VA первой полипептидной цепи связан с четвертым доменом VA второй полипептидной цепи с образованием антиген-связывающего сайта для первого антигена A;- второй домен VB первой полипептидной цепи связан с третьим доменом VB второй полипептидной цепи с образованием антиген-связывающего сайта для второго антигена B;- третий домен VB первой полипептидной цепи связан со вторым доменом VB второй полипептидной цепи с образованием антиген-связывающего сайта для второго антигена B; и- четвертый домен VA первой полипептидной цепи связан с первым доменом VA второй полипептидной цепи с образованием антиген-связывающего сайта для первого антигена A.2. Антиген-связывающая молекула по п. 1, отличающаяся тем, что первая и вторая полипептидные цепи нековалентно связаны.3. Антиген-связывающая молекула по п. 1 или 2, отличающаяся тем, что указанная антиген-связывающая мо�1. A dimeric antigen-binding molecule consisting of a first and second polypeptide chain, each of the first and second polypeptide chains containing: - a first VA domain, which is a variable domain of a light chain specific for the first antigen A; - a second VB domain being the heavy chain variable domain specific for the second B antigen; the third VB domain being the light chain variable domain specific for the second B antigen; and - the fourth VA domain, which is the variable domain of the heavy chain specific for the first antigen A, wherein said domains are located in each of said first and second polypeptide chains in order VA-VB-VB-VA from the N-terminus to C- at the end of said polypeptide chains, and - the first VA domain of the first polypeptide chain is linked to the fourth VA domain of the second polypeptide chain to form an antigen-binding site for the first antigen A; - the second VB domain of the first polypeptide chain is connected to the third VB domain of the second polypeptide chain aniem antigen-binding site for a second antigen B; - VB third domain of the first polypeptide chain is linked to a second domain VB second polypeptide chain to form an antigen-binding site for a second antigen B; and the fourth VA domain of the first polypeptide chain is coupled to the first VA domain of the second polypeptide chain to form an antigen binding site for the first A.2 antigen. The antigen binding molecule according to claim 1, characterized in that the first and second polypeptide chains are non-covalently linked. The antigen binding molecule according to claim 1 or 2, characterized in that said antigen binding molecule
Claims (15)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/062673 WO2013013700A1 (en) | 2011-07-22 | 2011-07-22 | Multivalent antigen-binding fv molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013157040A true RU2013157040A (en) | 2015-08-27 |
RU2613368C2 RU2613368C2 (en) | 2017-03-16 |
Family
ID=44719851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013157040A RU2613368C2 (en) | 2011-07-22 | 2011-07-22 | Multivalent antigen-binding fv molecule |
Country Status (8)
Country | Link |
---|---|
JP (1) | JP5938473B2 (en) |
CN (1) | CN103687879B (en) |
AU (1) | AU2011373925B2 (en) |
BR (1) | BR112014001573B8 (en) |
CA (1) | CA2842649C (en) |
MX (1) | MX347829B (en) |
RU (1) | RU2613368C2 (en) |
WO (1) | WO2013013700A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2785766C2 (en) * | 2015-10-13 | 2022-12-13 | Аффимед Гмбх | MULTIVALENT Fv-ANTIBODIES |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
TWI688572B (en) | 2015-01-26 | 2020-03-21 | 美商宏觀基因股份有限公司 | Multivalent molecules comprising dr5-binding domains |
CN108289949B (en) | 2015-05-29 | 2022-04-12 | 安普希韦纳治疗公司 | Methods of use of bispecific CD33 and CD3 binding proteins |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
GEP20227438B (en) | 2015-07-30 | 2022-11-10 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
EP3389714A4 (en) | 2015-12-14 | 2019-11-13 | MacroGenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
AR108034A1 (en) | 2016-02-17 | 2018-07-11 | Macrogenics Inc | MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME |
JP7002467B2 (en) | 2016-04-15 | 2022-01-20 | マクロジェニクス,インコーポレーテッド | New B7-H3 binding molecule, its antibody drug conjugate, and how to use it |
EP3558368A4 (en) | 2016-12-23 | 2020-12-30 | MacroGenics, Inc. | Adam9-binding molecules, and methods of use thereof |
CA3221995A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
US11884732B2 (en) | 2017-02-20 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
EP3589655B1 (en) | 2017-02-28 | 2022-10-26 | Affimed GmbH | Tandem-diabody for cd16a-directed nk-cell engagement |
US20200181263A1 (en) * | 2017-06-05 | 2020-06-11 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa |
MX2020004300A (en) | 2017-10-26 | 2020-08-13 | Saint Gobain | Vehicle add-on part having an integrated camera module. |
SG11202005557TA (en) | 2017-12-12 | 2020-07-29 | Macrogenics Inc | Bispecific cd 16-binding molecules and their use in the treatment of disease |
JP2021512630A (en) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Antibody variable domain targeting NKG2D receptor |
WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
JP7383704B2 (en) * | 2018-06-07 | 2023-11-20 | カリナン オンコロジー インコーポレイテッド | Multispecific binding proteins and their uses |
RU2738802C1 (en) | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Complementarity-determining regions for binding cd3 and a bispecific antigen-binding molecule containing thereof |
GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU690528B2 (en) | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
DE19819846B4 (en) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
AU2003227504A1 (en) * | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
JPWO2005056605A1 (en) * | 2003-12-12 | 2007-12-06 | 中外製薬株式会社 | Modified antibody that recognizes a trimer or higher receptor |
TW200722518A (en) * | 2005-03-31 | 2007-06-16 | Chugai Pharmaceutical Co Ltd | Sc(fv)2 structural isomers |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
WO2010109924A1 (en) * | 2009-03-25 | 2010-09-30 | 国立大学法人東北大学 | Lh-type bispecific antibody |
EP2361936B1 (en) * | 2010-02-25 | 2016-04-20 | Affimed GmbH | Antigen-binding molecule and uses thereof |
-
2011
- 2011-07-22 RU RU2013157040A patent/RU2613368C2/en active
- 2011-07-22 CA CA2842649A patent/CA2842649C/en active Active
- 2011-07-22 AU AU2011373925A patent/AU2011373925B2/en not_active Ceased
- 2011-07-22 BR BR112014001573A patent/BR112014001573B8/en not_active IP Right Cessation
- 2011-07-22 JP JP2014520541A patent/JP5938473B2/en not_active Expired - Fee Related
- 2011-07-22 CN CN201180072477.5A patent/CN103687879B/en active Active
- 2011-07-22 MX MX2014000816A patent/MX347829B/en active IP Right Grant
- 2011-07-22 WO PCT/EP2011/062673 patent/WO2013013700A1/en active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2785766C2 (en) * | 2015-10-13 | 2022-12-13 | Аффимед Гмбх | MULTIVALENT Fv-ANTIBODIES |
RU2785766C9 (en) * | 2015-10-13 | 2023-09-27 | Аффимед Гмбх | MULTIVALENT Fv-ANTIBODIES |
Also Published As
Publication number | Publication date |
---|---|
BR112014001573B8 (en) | 2022-11-08 |
CA2842649C (en) | 2020-01-21 |
BR112014001573A2 (en) | 2017-02-21 |
MX2014000816A (en) | 2014-07-09 |
CN103687879B (en) | 2016-05-04 |
CN103687879A (en) | 2014-03-26 |
JP2014527515A (en) | 2014-10-16 |
WO2013013700A1 (en) | 2013-01-31 |
RU2613368C2 (en) | 2017-03-16 |
MX347829B (en) | 2017-05-15 |
AU2011373925A1 (en) | 2014-01-16 |
BR112014001573B1 (en) | 2022-08-30 |
AU2011373925B2 (en) | 2016-04-28 |
JP5938473B2 (en) | 2016-06-22 |
CA2842649A1 (en) | 2013-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013157040A (en) | POLYVALENT ANTIGEN-BINDING FV-MOLECULE | |
HRP20210739T1 (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
CY1120414T1 (en) | ANTIBODIES CONNECTED TO NO40 AND THEIR USES | |
RU2017105120A (en) | CD3-BINDING DOMAIN | |
AR075504A1 (en) | MOLECULES OF ANTIBODIES THAT HAVE SPECIFICITY FOR THE HUMAN OX40 | |
AR077088A1 (en) | BISPECIFIC PROTEINS OF ANTIGEN UNION | |
JP2017504578A5 (en) | ||
NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
CA2808482C (en) | Methods for the generation of multispecific and multivalent antibodies | |
JP2014158485A5 (en) | ||
EA201400568A1 (en) | ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS | |
RU2014120154A (en) | STABLE ANTIBODIES COMBINING WITH MULTIPLE ANTIGENS | |
JP2017529067A5 (en) | ||
PE20220495A1 (en) | CHIMERIC ANTIGENIC RECEPTORS AND BINDING AGENTS TARGETING DLL3 | |
RU2015129762A (en) | SINGLE-LINK FabFv ANTIBODIES AND METHODS FOR PRODUCING THEM | |
JP2014505463A5 (en) | ||
AR080501A1 (en) | ANTIBODIES ANTI FACTOR ANTIGENIC DETERMINANT OF PROGRAMMED DEATH 1 (ANTI-PD1) | |
ES2683847T3 (en) | Cytotoxic immunoglobulin | |
SG195077A1 (en) | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes | |
TR201902400T4 (en) | Multivalent antigen binding Fv molecule. | |
UA106607C2 (en) | SPECIFIC BINDING PROTEINS AND THEIR APPLICATIONS | |
AR091605A1 (en) | ANTI-MESOTHELINE UNION PROTEINS | |
RU2016106577A (en) | SPECIFICALLY BINDING ANTIBODY SITES EGFRvIII | |
JP2016536322A5 (en) | ||
RU2014100111A (en) | MOLECULES RELATING TO Psl Pseudomonas, AND WAYS OF THEIR APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant |